Protara Therapeutics continues to advance its late-stage clinical pipeline, focusing heavily on key milestones such as completing patient enrollment for the registrational cohorts of its TARA-002 trials in non-muscle invasive bladder cancer and lymphatic malformations. The biopharmaceutical enterprise reported a robust cash position intended to fund planned operations well into future years, while sharing positive interim safety and efficacy data across its ongoing clinical study updates.